Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.

The grant application included the Phase 1/2 protocol BDP-ENT-01, which is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in four dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of DOR201, as well as the preliminary efficacy of DOR201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be initiated in 2009.

Acute radiation enteritis is caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms. Radiation enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.

"Radi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... CHICAGO , July 29, 2014  Roche (SIX: ... American Association for Clinical Chemistry (AACC) 2014 Clinical Lab ... focused on the unique ways Roche is partnering with ... "Our customers tell us every day that they,re ... value they deliver in their labs and offices," said ...
(Date:7/29/2014)... and TORONTO , ... Corporation (OTCBB: ESAQ), an emerging pharmaceutical company ... of improved novel formulations and alternative dosage ... expansion of its pharmaceutical development implementing its sub-micron ... large molecule drugs that will address indications ...
(Date:7/29/2014)... July 29, 2014 Cynosure, Inc. ... laser- and light-based aesthetic treatment systems for high-volume applications, ... June 30, 2014. Second-quarter 2014 financial results incorporate the ... June 24, 2013. Second-Quarter 2014 ... 45% to $72.6 million , Non-GAAP net income ...
Breaking Medicine Technology:Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... 2011 Luminex Corporation (Nasdaq: LMNX ) ... 2011 Global Healthcare Conference to be held June 6-9 ... The investor presentation by Patrick J. ... 9:00 a.m. Eastern time on Tuesday, June 7, 2011.  The ...
... MALVERN, Pa., May 31, 2011 Fujirebio Diagnostics, ... (FDA) has granted 510 (k) clearance to the CYFRA 21-1™ ... disease and treatment of lung cancer patients. This is the ... use in the management of patients with lung cancer. ...
Cached Medicine Technology:Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference 2Fujirebio Diagnostics, Inc. Receives FDA 510 (k) Clearance for First Biomarker to Monitor Lung Cancer 2
(Date:7/29/2014)... Winter is here down under, and it ... central business district. That is, until a troop of ... otherwise ordinary day into a celebration—a celebration of drug-free ... of The Truth About Drugs, a drug prevention initiative ... woke up the city with a rousing performance of ...
(Date:7/29/2014)... July 29, 2014 DailyGossip.org reveals in its ... by someone who can perfectly understand patients and what they ... , Ellie Gadsby is the author of the new program. ... After years of suffering, Ellie started her very own research. ... remedies. , The author of the Get Rid of Cold ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Regardless of ... needs a special someone to share those with. Love ... special someone. , Love is also about overcoming ... However, to have that perfect relationship, women need to ... more about the Enchant Him program, please visit the ...
(Date:7/29/2014)... 2014 (HealthDay News) -- Want young children to embrace ... that,s healthy is good for them. Doing so will ... new study suggests. "Parents and caregivers who are ... better off simply serving the food without saying anything ... food actually is," said study authors Michal Maimaran, of ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells are ... and effectiveness, according to a review in the August ... , the official medical journal of the American ... offer tremendous potential, but the marketplace is saturated with ... at risk," write Dr Michael T. Longaker of Stanford ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2
... WASHINGTON, Nov. 12 U.S. ... Assurance (NCQA) today released the fifth annual edition of ... . Published at the start of open-enrollment season, ... the 2009-10 Best Health Insurance Plans guide provides consumers ...
... Mary Elizabeth Derig, of Seattle, Washington, has been ... her outstanding contributions and achievements in the field of ... ) , ABOUT MARY ELIZABETH DERIG ... career as a Registered Nurse including work in post ...
... 12 Satellite Healthcare, one of the nation,s first and ... of nephrology research, today announced the opening of a new ... to Satellite Healthcare,s rapidly expanding presence in the central valley, ... those affected with Chronic Kidney Disease (CKD). , "This new ...
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... Drive stepper motor linear actuator. The IDEA Drive is an integrated linear actuator, electronic ... Interface). , ... November 13, 2009 -- Haydon Kerk Motion Solutions introduces the Haydon IDEA™ Drive stepper ...
... ... simple holiday recipe for Holly Jolly Biscotti, which showcases the peak-season flavors of Texas citrus ... way to promote a good-for-you diet throughout the holidays not just for yourself, but everyone ... ...
Cached Medicine News:Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 2Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 3Health News:U.S. News Media Group and NCQA Release 2009-10 Rankings of America's Best Health Insurance Plans 4Health News:Mary Elizabeth Derig Recognized by Strathmore's Who's Who Worldwide Publication 2Health News:Satellite Dialysis Celebrates the Opening of Its Newest Center in Tracy, CA 2Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Haydon Kerk Motion Solutions Introduces the IDEA Drive 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 2Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 3Health News:Dip into a Healthy Holiday with the Taste of Texas Oncology's Holly Jolly Biscotti 4
... INTERING Vascular Graft, the newest vascular graft ... a leader in vascular surgical products for ... by reducing kinking and compression problems ... new graft provides all of the benefits ...
... Vikingselect Intra-Operative Monitoring (IOM). ... the brain and nervous system. Time-stamped ... and amplitudes. Quick visual overview of ... trendplots on-line. Special software allows simultaneous ...
... especially designed for surgical monitoring and Intensive ... and is equipped with two headboxes and ... be independently configured as either a true ... amplifiers are based on the Firewire (IEEE1394TM) ...
... management software - was designed by ... improvement tool helps diabetes care providers ... bridges medicine with technology by providing ... information technology product. This diabetes ...
Medicine Products: